Abstract
Oral methotrexate is the benchmark against which other disease-modifying anti rheumatic drugs are measured. The use of parenteral methotrexate for those failing to tolerate or respond to oral therapy is accepted, but indications for its use and its place in the therapeutic ladder have not been fully investigated. We assessed the use of parenteral methotrexate (MTX) in our rheumatoid arthritis (RA) population and compared the characteristics of these patients to a matched group of those on oral therapy. We compared response rates to each approach using DAS 28 scores, ESR and visual analogue scales. Inferences on costs of parenteral therapy were made and predictors of response defined. We found that 10% of our total RA patient population were on parenteral methotrexate, having failed to tolerate or respond to oral therapy. Seventy-five percent of these met the criteria for the use of anti-tumour necrosis factor (TNF) agents. Overall response rates were equivalent to those obtained by responders to oral MTX. Patients on parenteral therapy were younger and were more likely to have extreme values of body mass index (BMI) than those on oral therapy. The approach was economically viable, although many patients unnecessarily attended hospital to receive their injections. We advocate consideration of parenteral MTX in all RA patients unresponsive to oral therapy prior to treatment with anti-TNF therapy. Response to parenteral therapy can be predicted by low BMI (below 22 kg/m2), possibly as a result of malabsorption, or by high BMI (over 30) as a result of gastrointestinal intolerance. A mechanism to deliver this option through self-administration in the community should be encouraged.
References
Weinblatt M, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC et al (1994) Methotrexate in rheumatoid arthritis: a five year prospective multicenter study. Arthritis Rheum 37:1492–1498
Kremer JM (1997) Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 40:984–985
Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 29:1631–1638
Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF (2005) The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 44:61–66
Furst DE, Keystone EC, Kirkham B, Fleischman R, Mease P, Breedveld FC et al (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 67:ii2–iii25
American College of Rheumatology (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328–346
Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology 41:1367–1374
van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ (2002) Homocysteine and folate status in methotrexate treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41:658–665
Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, Laar M (2006) Splitting high-dose oral methotrexate improves bioavalability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 33:481–485
El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kremer JR et al (2007) Obesity increases oesophageal acid exposure. Gut 56:749–755
Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V (2004) Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 50:364–371
Braun J, Kastner P, Flaxenburg P, Wahrisch J, Hanke P, Demary W et al (2008) Comparison of the clinical efficacy and safety of subcutaneous methotrexate in patients with active rheumatoid arthritis: results of a six month multicenter randomized double blind controlled phase IV trial. Arthritis Rheum 58:73–81
Kremer JM, Hamilton RA (1997) Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Brit J Rheumatol 36:86–90
Collins K, Aspey H, Todd A, Rynne M, Saravanan V, Kelly CA (2008) Methotrexate pneumonitis precipitated by switching from oral to subcutaneous administration. Rheumatology 47:109–110
Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, Laar M (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31:645–648
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432
Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW et al (2003) Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423–426
Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43:22–29
Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF et al (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56:1765–1775
Hider SL, Silman AJ, Thomson W, Lunt M, Bunn D, Symmons DPM (2009) Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 58:57–62
Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P et al (2003) Relationship between body mass and gastro-oesophageal reflux symptoms: the Bristol Helicobacter Project. Int J Epidemiol 32:645–650
Cronstein BN (1996) Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 39:1951–1960
Ranganathan P, McLeod HL (2006) Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366–1377
Criswell LA, Lum RF, Turner KN, Peden EA, Means GD, Derry MJ et al (2002) The HLA-DRB1 shared epitope as a predictor of response to treatment of RA with methotrexate and etanercept. Arthritis Rheum 46(Suppl):376
Lee YC, Cui J, Costenbader JH, Shadick NA, Weinblatt ME, Karlson EW (2009) Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology 48:613–617
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Additional information
No source of funding was given to support this study.
We agree to Clinical Rheumatology having the licence to publish this paper and confirm that it is not under consideration by any other journal.
Rights and permissions
About this article
Cite this article
Mainman, H., McClaren, E., Heycock, C. et al. When should we use parenteral methotrexate?. Clin Rheumatol 29, 1093–1098 (2010). https://doi.org/10.1007/s10067-010-1500-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1500-9